The Detection Performance of 18F-Prostate-Specific Membrane Antigen-1007 PET/CT in Primary Prostate Cancer A Systemic Review and Meta-analysis

被引:13
作者
Huang, Ya-Ting [1 ,2 ]
Tseng, Neng-Chuan [3 ,4 ]
Chen, Yen-Kung [5 ,6 ]
Huang, Kuo-How [7 ]
Lin, Hsiu-Ying [7 ,8 ]
Huang, Ya-Yao [1 ,9 ,10 ]
Hwang, Thomas I. S. [11 ,12 ,13 ]
Ou, Yen-Chuan [14 ,15 ]
机构
[1] Primo Biotechnol Co Ltd, Taipei, Taiwan
[2] Camillian St Marys Hosp Luodong, Dept Med Educ & Res, Yilan, Taiwan
[3] Tungs Taichung Metro Harbor Hosp, Div Nucl Med, Taichung, Taiwan
[4] China Med Univ, Dept Publ Hlth, Taichung, Taiwan
[5] Shin Kong Wu Ho Su Mem Hosp, Nucl Med & PET Ctr, Taipei, Taiwan
[6] Fu Jen Catholic Univ, Sch Med, New Taipei, Taiwan
[7] Natl Taiwan Univ Hosp, Dept Urol, Taipei, Taiwan
[8] Natl Taiwan Univ Hosp, Dept Nursing, Taipei, Taiwan
[9] Natl Taiwan Univ, Coll Med, Inst Med Device & Imaging, Taipei, Taiwan
[10] Natl Taiwan Univ, Mol Imaging Ctr, Taipei, Taiwan
[11] Shin Kong Wu Ho Su Mem Hosp, Dept Surg, Div Urol, Taipei, Taiwan
[12] Fu Jen Catholic Univ, Sch Med, Div Urol, New Taipei, Taiwan
[13] Taipei Med Univ, Dept Urol, Taipei, Taiwan
[14] Tungs Taichung Metro Harbor Hosp, Dept Surg, Div Urol, Taichung, Taiwan
[15] Tungs Taichung Metro Harbor Hosp, Dept Res, Taichung, Taiwan
关键词
F-18-PSMA-1007; PET; CT; prostate-specific membrane antigen; prostate cancer; PSMA; BIOPSY; BIODISTRIBUTION; RADIOTRACERS; RISK; F-18; MRI; MEN; PSA;
D O I
10.1097/RLU.0000000000004228
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background Multiple tools are now available to determine the requirement for a biopsy to diagnose prostate cancer, and PET/CT with radiolabeled prostate-specific membrane antigen (PSMA)-targeting radiotracers has been recommended for detecting primary prostate cancer. Particularly, the radiotracer F-18-PSMA-1007 was found to be more favorable for primary tumors compared with other PSMA-targeting radiotracers because of its low clearance via the urinary tract and better image resolution. Thus, we performed a systematic review and meta-analysis to more accurately evaluate the detection performance of F-18-PSMA-1007 PET/CT in primary prostate cancer patients. Methods An update on the databases of PubMed/MEDLINE, EMBASE, and Cochrane Library for comprehensive literature search was performed on September 30, 2021. The pooling detection rate was calculated on a per-patient basis. The pooling median of the SUVmax was analyzed from the included studies. Furthermore, the positive predictive value of F-18-PSMA-1007 PET/CT with pathologic lesions was analyzed using the criterion standard. Results Twelve studies (540 patients total) were included in the meta-analysis. The overall pooling detection rate of F-18-PSMA-1007 per patient was 94%, and the pooling median of SUVmax located at the intraprostate tumor was 16 (range, 3.7-77.7). The positive predictive value of F-18-PSMA-1007 per lesion with histopathological validation was 0.90, detecting regional lymph node metastasis was 0.94, and detecting localized prostatic tumors was 0.84. Conclusions In the current meta-analysis, we revealed the excellent performance of F-18-PSMA-1007 to detect localized prostatic tumor lesions and regional lymph node metastasis. Moreover, the uptake of localized tumors in primary prostate cancer was nearly liver uptake and may be considered a suspicious malignancy if it was equal to or greater than the liver uptake.
引用
收藏
页码:755 / 762
页数:8
相关论文
共 61 条
[1]   A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE) [J].
Anttinen, Mikael ;
Ettala, Otto ;
Malaspina, Simona ;
Jambor, Ivan ;
Sandell, Minna ;
Kajander, Sami ;
Rinta-Kiikka, Irina ;
Schildt, Jukka ;
Saukko, Ekaterina ;
Rautio, Pentti ;
Timonen, Kirsi L. ;
Matikainen, Tuomas ;
Noponen, Tommi ;
Saunavaara, Jani ;
Loyttyniemi, Eliisa ;
Taimen, Pekka ;
Kemppainen, Jukka ;
Dean, Peter B. ;
Sequeiros, Roberto Blanco ;
Aronen, Hannu J. ;
Seppanen, Marko ;
Bostrom, Peter J. .
EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (04) :635-644
[2]   Diagnostic Role of 18F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review [J].
Awenat, Salam ;
Piccardo, Arnoldo ;
Carvoeiras, Patricia ;
Signore, Giovanni ;
Giovanella, Luca ;
Prior, John O. ;
Treglia, Giorgio .
DIAGNOSTICS, 2021, 11 (03)
[3]   Usefulness of MRI targeted prostate biopsy for detecting clinically significant prostate cancer in men with low prostate-specific antigen levels [J].
Bang, Seokhwan ;
Yu, Jiwoong ;
Chung, Jae Hoon ;
Song, Wan ;
Kang, Minyong ;
Sung, Hyun Hwan ;
Jeon, Hwang Gyun ;
Jeong, Byong Chang ;
Seo, Seong Il ;
Lee, Hyun Moo ;
Jeon, Seong Soo .
SCIENTIFIC REPORTS, 2021, 11 (01)
[4]   Positron emission tomography (PET) in primary prostate cancer staging and risk assessment [J].
Bednarova, Sandra ;
Lindenberg, Maria L. ;
Vinsensia, Maria ;
Zuiani, Chiara ;
Choyke, Peter L. ;
Turkbey, Baris .
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2017, 6 (03) :413-423
[5]   68Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology [J].
Berger, I ;
Annabattula, C. ;
Lewis, J. ;
Shetty, D., V ;
Kam, J. ;
Maclean, F. ;
Arianayagam, M. ;
Canagasingham, B. ;
Ferguson, R. ;
Khadra, M. ;
Ko, R. ;
Winter, M. ;
Loh, H. ;
Varol, C. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (02) :204-211
[6]   Detection of prostate cancer with18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial [J].
Bodar, Y. J. L. ;
Jansen, B. H. E. ;
van der Voorn, J. P. ;
Zwezerijnen, G. J. C. ;
Meijer, D. ;
Nieuwenhuijzen, J. A. ;
Boellaard, R. ;
Hendrikse, N. H. ;
Hoekstra, O. S. ;
van Moorselaar, R. J. A. ;
Oprea-Lager, D. E. ;
Vis, A. N. .
WORLD JOURNAL OF UROLOGY, 2021, 39 (07) :2439-2446
[7]   E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET [J].
Ceci, Francesco ;
Oprea-Lager, Daniela E. ;
Emmett, Louise ;
Adam, Judit A. ;
Bomanji, Jamshed ;
Czernin, Johannes ;
Eiber, Matthias ;
Haberkorn, Uwe ;
Hofman, Michael S. ;
Hope, Thomas A. ;
Kumar, Rakesh ;
Rowe, Steven P. ;
Schwarzenboeck, Sarah M. ;
Fanti, Stefano ;
Herrmann, Ken .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (05) :1626-1638
[8]  
Chen M., 2019, Q J NUCL MED
[9]   Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging [J].
Chikatamarla, Venkata Avinash ;
Okano, Satomi ;
Jenvey, Peter ;
Ansaldo, Alexander ;
Roberts, Matthew J. ;
Ramsay, Stuart C. ;
Thomas, Paul A. ;
Pattison, David A. .
EJNMMI RESEARCH, 2021, 11 (01)
[10]   Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration [J].
Cohen, Jeremie F. ;
Deeks, Jonathan J. ;
Hooft, Lotty ;
Salameh, Jean-Paul ;
Korevaar, Daniel A. ;
Gatsonis, Constantine ;
Hopewell, Sally ;
Hunt, Harriet A. ;
Hyde, Chris J. ;
Leeflang, Mariska M. ;
Macaskill, Petra ;
McGrath, Trevor A. ;
Moher, David ;
Reitsma, Johannes B. ;
Rutjes, Anne W. S. ;
Takwoingi, Yemisi ;
Tonelli, Marcello ;
Whiting, Penny ;
Willis, Brian H. ;
Thombs, Brett ;
Bossuyt, Patrick M. ;
McInnes, Matthew D. F. .
BMJ-BRITISH MEDICAL JOURNAL, 2021, 372